William Blair analyst Raju Prasad downgraded Audentes Therapeutics (NASDAQ: BOLD) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Audentes Therapeutics click here. For more ratings news on Audentes Therapeutics click here.

Shares of Audentes Therapeutics closed at $29.56 yesterday.